Caribou Biosciences | IPO Presentation Deck | 44 slides · page 25 of 44
The slide details the transition from healthy donor leukapheresis through genetic modification (using AAV, Cas9, and chRDNA) to final cryopreservation and treatment.
Pitch deck · solution · present_solution · sparse density
Slide locked Sign in to view
Slide schematic 3/3
diagram 1/1 paragraph 1/1 title 1/1
Components 3
process paragraph headline
Tools 1
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 1